Pardo I, Levinson A I
Clin Immunol Immunopathol. 1983 Oct;29(1):29-34. doi: 10.1016/0090-1229(83)90004-1.
The level of circulating cells secreting IgG, IgM, and IgA (IgSC) provides insight into the degree of in vivo polyclonal B-cell activation (PBA). Patients with rheumatoid arthritis (RA) exhibit abnormalities in humoral immune responses suggestive of augmented in vivo polyclonal B-cell activation. Therefore, a protein A reverse hemolytic plaque assay was used to measure the level of circulating IgSC in 32 RA patients. The mean level of circulating IgSC in RA patients was 3602 +/- 747 (SEM) compared to a mean of 1407 +/- 443 in patients with other types of arthritis and 1253 +/- 216 (P less than 0.02) in healthy volunteers. Levels found in RA patients did not appear to reflect disease activity or concomitant corticosteroid therapy. However, a subset of RA patients receiving gold therapy had levels of IgSC (1381 +/- 501) similar to those seen in healthy volunteers (P greater than 0.5). These data are consistent with augmented in vivo polyclonal B-cell activation in RA. In addition they suggest that gold affects mechanisms controlling in vivo B-cell activation.
分泌IgG、IgM和IgA的循环细胞（IgSC）水平可反映体内多克隆B细胞激活（PBA）的程度。类风湿性关节炎（RA）患者的体液免疫反应存在异常，提示体内多克隆B细胞激活增强。因此，采用蛋白A反向溶血空斑试验检测了32例RA患者循环IgSC的水平。RA患者循环IgSC的平均水平为3602±747（标准误），而其他类型关节炎患者的平均水平为1407±443，健康志愿者的平均水平为1253±216（P<0.02）。RA患者的检测水平似乎并不反映疾病活动度或同时进行的皮质类固醇治疗情况。然而，接受金制剂治疗的一部分RA患者的IgSC水平（1381±501）与健康志愿者相似（P>0.5）。这些数据与RA患者体内多克隆B细胞激活增强一致。此外，它们提示金制剂会影响体内控制B细胞激活的机制。
